We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expression of Longevity Genes in Response to Extended Fasting (FEELGOOD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01059760
Recruitment Status : Completed
First Posted : February 1, 2010
Results First Posted : July 17, 2017
Last Update Posted : July 17, 2017
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to evaluate the effect of fasting on physical changes associated with cardiovascular disease.

Condition or disease Intervention/treatment
Cardiovascular Disease Behavioral: Fasting First Behavioral: Fed First

Detailed Description:
Coronary heart disease (CHD) is the largest contributor to morbidity and mortality in the Western world and is associated with high-calorie diet, high body mass, and a variety of other factors. CHD can lead to myocardial infarction (MI) and other embolic events. A growing body of evidence suggests that relatively low caloric intake in the diets of a variety of animals increases longevity and preliminary evidence among humans indicates that such caloric restriction reduces risk factors for CHD, including cholesterol levels, blood pressure, glucose, and obesity. Caloric restriction has also been shown to alter the expression of certain genes, especially the forkhead box (FOX) O and sirtuin (SIRT) genes whose over-expression has been shown to increase longevity in animal models. Extended avoidance of caloric intake, also called fasting or short-term starvation, has been shown to increase expression of the FOXA genes that have similar sequence and function as the FOXO genes and that have been shown to increase longevity among animals regardless of FOXO function. We recently demonstrated that the risk of CHD was significantly lower among patients who reported a history of routine periodic extended fasting. The two primary hypotheses for this observation are that fasting may improve individual ability to control dietary intake or that fasting may initiate a cascade of protective mechanisms that preserve cellular and metabolic health.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Expression of Longevity Genes in Response to Extended Fasting
Study Start Date : January 2010
Primary Completion Date : August 2010
Study Completion Date : October 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Fasting Day First
28±4 hours of water-only fasting followed by 28±4 hours fed
Behavioral: Fasting First
28±4 hours of water-only fasting followed by 28±4 hours fed
Fed Day First
28± 4 hours fed followed by 28± 4 hours of fasting
Behavioral: Fed First
28± 4 hours fed followed by 28± 4 hours of fasting


Outcome Measures

Primary Outcome Measures :
  1. Change From Baseline in Participant Glucose When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  2. Change From Baseline in Participant Human Growth Hormone (HGH) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  3. Change From Baseline in Participant Insulin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  4. Change From Baseline in Participant Homeostasis Model Assessment-Insulin Resistance (HOMA-IR) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
    HOMA-IR is used to measure the severity of insulin resistance. Healthy Range: 1.0 (0.5-1.4) Less than 1.0 is optimal Above 1.9 indicates early insulin resistance Above 2.9 indicates significant insulin resistance

  5. Change From Baseline in Participant Glycogen-Like Protein-1 (GLP-1) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  6. Change From Baseline in Participant Adiponectin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  7. Change From Baseline in Participant Fibroblast Growth Factor-21 (FGF-21) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  8. Change From Baseline in Participant White Blood Cell Count (WBC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  9. Change From Baseline in Participant Hemoglobin When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  10. Change From Baseline in Participant Red Blood Cell Count (RBC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  11. Change From Baseline in Participant Hematocrit When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  12. Change From Baseline in Participant Platelet Count When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  13. Change From Baseline in Participant Mean Corpuscular Volume (MCV) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  14. Change From Baseline in Participant Mean Corpuscular Hemoglobin (MCH) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  15. Change From Baseline in Participant Mean Corpuscular Hemoglobin Concentration (MCHC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  16. Change From Baseline in Participant Red Cell Distribution Width (RDW) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  17. Change From Baseline in Participant Mean Platelet Volume (MPV) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  18. Change From Baseline in Participant Bicarbonate When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  19. Change From Baseline in Participant Sodium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  20. Change From Baseline in Participant Chloride When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  21. Change From Baseline in Participant Blood Urea Nitrogen (BUN) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  22. Change From Baseline in Participant Calcium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  23. Change From Baseline in Participant Potassium When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  24. Change From Baseline in Participant Creatinine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  25. Change From Baseline in Participant Total Cholesterol (TC) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  26. Change From Baseline in Participant Low-Density Lipoprotein Cholesterol (LDL-C) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  27. Change From Baseline in Participant High-Density Lipoprotein Cholesterol (HDL-C) When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  28. Change From Baseline in Participant Triglycerides When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  29. Change From Baseline in Participant TC/HDL Ratio When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  30. Change From Baseline in Participant Weight When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  31. Change From Baseline in Participant Waist Circumference When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  32. Change From Baseline in Participant Systolic Blood Pressure (SBP), Supine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  33. Change From Baseline in Participant Diastolic Blood Pressure (DBP), Supine When Fasting and Fed [ Time Frame: Baseline and 3 days ]
  34. Change From Baseline in Participant High Sensitivity C-Reactive Protein (hsCRP) When Fasting and Fed [ Time Frame: Baseline and 3 days ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. The volunteer (male or non-pregnant female, any ethnicity) must be >18 years of age.
  2. The volunteer must either have a body mass index of 25.0-35.0 kg/m2 or the combination of a body mass index of 18.5-24.9 kg/m2 and two or more previously or currently measured symptoms of the metabolic syndrome (fasting glucose≥110 mg/dL, triglycerides≥150 mg/dL, high-density lipoprotein cholesterol<40 mg/dL in males or <50 mg/dL in females, systolic blood pressure≥130 mmHg or diastolic blood pressure≥85 mmHg, or waist circumference≥40 inches in males or ≥36 inches in females [glucose and cholesterol levels may be self-reported]).
  3. The volunteer has not routinely participated in caloric restriction (deliberate limitation of caloric intake of <80% than the FDA-recommended daily caloric intake) within the last 2 years, has not participated in extended fasting (>12 hours at a time) for at least a year, and does not deliberately skip meals as a routine dietary practice.

Exclusion Criteria:

  1. Body mass index <18.5 or >35 kg/m2.
  2. Current active cancer treatment, treatment with immunosuppressive medications, or solid organ transplantation within 1 year.
  3. Presence of immunosuppressive disease, myocardial infarction, peripheral vascular disease, or stroke within the past year.
  4. Use of insulin.
  5. Although it is unlikely fasting will harm the pregnant or lactating woman, the dietary restrictions placed on the participant for the duration of the study may conflict with dietary recommendations for pregnant or lactating women. Women of child bearing potential, therefore, will meet an exclusion if they become pregnant.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01059760


Locations
United States, Utah
Intermountain Medical Center
Murray, Utah, United States, 84107-5701
Sponsors and Collaborators
Intermountain Health Care, Inc.
Investigators
Principal Investigator: Benjamin D Horne, PhD Intermountain Medical Center